NASDAQ · SVRA
Healthcare · Biotechnology
$5.49
Up+$0.10 (+1.82%)
Updated Aug 22, 2026, 1:50 AM
SID Score
4.3/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
SVRA closed at $5.49 after 20 trading sessions, down 0.36% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 20, 2026 | $5.52 | $5.59 | $5.26 | $5.49 | 2.54M |
| Aug 19, 2026 | $5.49 | $5.60 | $5.395 | $5.58 | 1.3M |
| Aug 18, 2026 | $5.33 | $5.43 | $5.285 | $5.37 | 1.51M |
| Aug 17, 2026 | $5.39 | $5.43 | $5.285 | $5.37 | 1.21M |
| Aug 14, 2026 | $5.25 | $5.40 | $5.14 | $5.38 | 1.65M |
| Aug 13, 2026 | $5.75 | $5.79 | $5.25 | $5.27 | 1.87M |
| Aug 12, 2026 | $5.91 | $5.92 | $5.575 | $5.70 | 1.18M |
| Aug 11, 2026 | $5.81 | $5.98 | $5.53 | $5.57 | 1.26M |
| Aug 10, 2026 | $5.82 | $5.93 | $5.63 | $5.73 | 1.21M |
| Aug 7, 2026 | $5.87 | $5.99 | $5.785 | $5.83 | 1.59M |
| Aug 6, 2026 | $5.52 | $5.81 | $5.52 | $5.79 | 1.01M |
| Aug 5, 2026 | $5.43 | $5.53 | $5.36 | $5.51 | 1.6M |
| Aug 4, 2026 | $5.45 | $5.525 | $5.375 | $5.41 | 1.36M |
| Aug 3, 2026 | $5.44 | $5.49 | $5.31 | $5.33 | 1.64M |
| Jul 31, 2026 | $5.54 | $5.63 | $5.35 | $5.46 | 1.17M |
| Jul 30, 2026 | $5.31 | $5.55 | $5.255 | $5.54 | 1.24M |
| Jul 29, 2026 | $5.34 | $5.40 | $5.18 | $5.28 | 1.26M |
| Jul 28, 2026 | $5.545 | $5.565 | $5.245 | $5.33 | 1.68M |
| Jul 27, 2026 | $5.56 | $5.68 | $5.43 | $5.43 | 3.79M |
| Jul 24, 2026 | $5.79 | $5.855 | $5.475 | $5.51 | 1.55M |
The latest Smart Investors Daily articles mentioning SVRA.
SVRA research
Company profile and research snapshot.
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 23, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 18, 2025 | Wells Fargo | Overweight | — |
| Nov 14, 2025 | Oppenheimer | Outperform | — |
| Nov 13, 2025 | Citizens | Market Outperform | — |
| Oct 23, 2025 | JMP Securities | Market Outperform | — |
No generated briefing is available yet.
Benzinga · Aug 11, 2026
MOLBREEVI* BLA PDUFA Target Action Date Set for November 22, 2026MOLBREEVI MAAs Under Review by the EMA and the U.K.’s MHRA; Decisions Expected in Q1 2027 and Q4 2026, respectivelyData Presented at ATS Showed
Benzinga · Aug 11, 2026
Savara (NASDAQ:SVRA) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 14.29 percent decrease over losses of $(0.14) per share from the
SeekingAlpha · Aug 5, 2026
Savara Inc. (SVRA) is revisited, focusing on its APAP BLA filing progress.
Benzinga · Mar 6, 2026
-- Day 74 Letter Received from the U.S. Food and Drug Administration (FDA) Indicated the Agency Has No Plans to Convene an Advisory Committee ---- Company has Submitted the Marketing Authorization Application (MAA) to
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning SVRA.
